Medical news
Each update carries a summary written by WellCareChina with AI assistance, the source name, the date, and a link to the original.
-
AI-assisted summary
Oral GLP-1 pill matches dapagliflozin on blood sugar in an 810-person phase 3 trial in China
A phase 3 trial published in Nature Medicine on 5 October 2026 compared safiglipron, an oral small-molecule GLP-1 receptor agonist taken without fasting or dietary restrictions, with dapagliflozin in 810 adults with type 2 diabetes at 98 sites in China. After 32 weeks the fall in HbA1c with safiglipron was non-inferior to dapagliflozin at all […]
-
AI-assisted summary
Phase 3 trial tests a sprayed medicine for nerve pain in diabetes
A phase 3 trial registered on ClinicalTrials.gov on 5 October 2026 will test YJ001, a spray developed by Zhejiang Hanmai Pharmaceutical Technology, in adults with painful diabetic peripheral neuropathy. The registration describes a two-part study: a randomised, double-blind, double-dummy, multi-centre phase 3 comparison against an approved reference medicine and placebo in about 400 participants, followed […]
-
AI-assisted summary
Study maps pain across the lifespan using data from 6.1 million people in 118 countries
A study published in Nature Medicine on 5 October 2026 pooled self-reported pain data from 6,125,459 participants across 902 population-based sources in 118 countries to build reference curves for pain across the lifespan. Pain prevalence ranged from about 2% for facial pain to about 40% for back pain, and was consistently higher in women at […]
-
AI-assisted summary
Cryoablation added before chemo-immunotherapy in operable lung cancer: a phase 2 trial
A phase 2 trial first posted on 2 October 2026 will test whether computed-tomography-guided cryo-thermal ablation added before toripalimab plus platinum chemotherapy improves results in resectable stage IB-IIIB non-small cell lung cancer. West China Hospital is the sponsor; the record lists nine sites in China and a planned enrolment of 40 participants. The registration says […]
-
AI-assisted summary
Review rounds up the mechanisms and drug evidence behind vascular calcification
A review in Signal Transduction and Targeted Therapy on 2 October 2026 surveys vascular calcification, the deposition of calcium-based mineral in artery walls that is linked to higher cardiovascular risk. The authors describe it as an actively regulated process driven by changes in vascular smooth-muscle cells, inflammation, oxidative stress and other pathways, and they review […]
-
AI-assisted summary
Urine test detects bladder cancer in a 683-sample study
Researchers report in Nature Medicine on 2 October 2026 a urine test that profiles cell-free RNA fragments (uRARE-seq) for bladder cancer detection. In 683 urine samples from patients with cancer and controls, the method detected localised bladder cancer with 95% sensitivity at 90% specificity and outperformed urine tumour DNA analysis in the comparison presented; the […]
-
AI-assisted summary
1,200-person phase 2 study aims at sustained clearance of hepatitis B surface antigen
The Second Affiliated Hospital of Chongqing Medical University has registered a phase 2 study, first posted on 1 October 2026, of a combination strategy whose goal is sustained loss of hepatitis B surface antigen — the outcome clinicians treat as the ideal endpoint of hepatitis B treatment. The record says fewer than 10% of patients […]
-
AI-assisted summary
First-in-human phase 1 trial reports safety data for an injected ferroptosis therapy in solid tumours
A first-in-human phase 1 trial published in Signal Transduction and Targeted Therapy on 1 October 2026 reports safety and early response data for CNSI-Fe, an experimental carbon nanoparticle-iron complex injected directly into solid tumours to trigger ferroptosis. Nineteen patients with refractory solid tumours received five dose levels (30-150 mg). The paper reports that the maximum […]
-
AI-assisted summary
Phase 3 trial opens in China for a new ovarian cancer maintenance treatment
AstraZeneca has registered a phase 3 trial, first posted on 1 October 2026, of torvutatug samrotecan plus bevacizumab against bevacizumab alone as first-line maintenance in advanced epithelial ovarian cancer without homologous recombination deficiency (HRD-negative). The study plans to enrol about 950 participants across 36 sites in China, according to the registry record, and its primary […]
-
AI-assisted summary
Review: CAR-T therapy is being tested beyond cancer, but nothing is approved there yet
A review published in Signal Transduction and Targeted Therapy on 1 October 2026 surveys chimeric antigen receptor T-cell (CAR-T) therapy outside cancer, including autoimmune diseases, ageing-related conditions and infections. The authors describe how CAR-T cells have changed the treatment of some blood cancers and how researchers are now testing the same approach against disease-specific cell […]